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n the last two decades, scientific interest regarding vitamin D has increased greatly. This trend has led to the publication of a large number of papers, unfortunately often of low quality and based on misinterpreted assumptions (1-3). Currently, the role of vitamin D and its supplementation is still controversial, at best. Many authors and opinion leaders seem to support the widespread use of vitamin D supplementation as a remedy for almost any health condition, advocating both its skeletal and extra-skeletal effects (4) . At the other end of the spectrum, others limit its usefulness solely for the prevention/ treatment of few rare bone diseases (5) . Given the extent of the whole topic, and the difference in the strength of the evidence supporting the skeletal effect versus the extra-skeletal ones, this article's focus will be on the former. Indeed, data on the efficacy of vitamin D supplementation on extraskeletal effects are still uncertain (3, 6) and caution should be adopted before applying the same conclusions in these settings. In Italy, in 2017, 10.5 Defined Daily Doses of cholecalciferol were used every 1000 subjects, with a total cost near to 234 million euros and with a per-capita cost of 3.89 euros (7) . Such extensive prescription is not necessarily appropriate. Arguably, a proportion of these subjects are young adults and/or people without any significant risk for vitamin D deficiency. However, we should not forget that roughly 22% of the Italian population is over 65 (8) and that the prevention strategies implemented in the last twenty years have shown to be effective in improving the overall vitamin D status in the elderly (9, 10), a population in whom its deficiency is notoriously more dangerous. This observation is striking especially in some Italian Regions such as in Veneto where, starting from the early 2000s, a community-based vitamin D supplementation campaign has been promoted by the two University Centres of Verona and Padua (11) . This initiative, directed towards subjects aged over 70, was associated, a few years after its initiation, with a 10% reduction in hip fracture incidence (10) . More recently, it has been even hypothesized to be one of the possible explanations for the declining trends in the incidence of hip fractures in Veneto in the population over 65 (years 2000 to 2011) (11). Indeed, hip fracture incidence in this Region appears to be in contrast with the global trend reported for the rest of Italy, where this strategy has not been adopted to date (11) . Recently, some large meta-analyses (5, 12) , combining the results of several small trials with those of a few large trials to increase the statistical power of the analyses, concluded that vitamin D supplementation has no beneficial effects. This statement may induce a great deal of further confusion and misunderstanding, not only in the general population, but also in the health authorities and in fellow clinicians. In the last systematic review and meta-analysis by Bolland et al. EDITORIAL sity (BMD) and thus that there is little justification for using vitamin D supplements to maintain or improve musculoskeletal health. They also state that supplementation is necessary only for the rare conditions of rickets and osteomalacia, which may occur after a prolonged lack of exposure to sunshine leading to 25OH-Vitamin D (25OHD) concentrations lower than 25 nmol/L (10 ng/mL) (5). We agree with Bolland that there is no benefit in treating healthy subjects, especially when they are not even vitamin D deficient. However, we fear that these strong conclusions might confuse fellow practitioners and lead them to stop prescribing vitamin D supplementation indiscriminately in all patients, except for the ones with established rickets or osteomalacia. The concern is even higher if we consider elderly frail subjects and those affected by osteoporosis and therefore receiving treatment with bone acting agents. It is known that, although bisphosphonates or denosumab are highly effective in preventing fractures (13) , some patients will nonetheless fracture every year. Vitamin D deficiency has been shown to be one of the strongest predictors for fragility fracture in these patients and a decisive determinant of the skeletal response to the treatment itself (14, 15) . An adequate vitamin D intake should be considered imperative not only in the setting of rickets or osteomalacia but, at least, in all these patients.
n CRITICAL ISSUES OF THE META-ANALYSIS FROM BOLLAND ET AL.
As with any systematic review, the choice of the included studies determines the quality and validity of the final results (and of the subsequent conclusions drawn from their interpretation). When analysing the meta-analysis from Bolland et al, one might wonder why two important placebocontrolled trials were excluded. In 1994 Chapuy et al. (16) showed in 3270 mobile elderly women that daily treatment with 1.2 g calcium and 800 IU of cholecalciferol was able to decrease the probability EDITORIAL Moreover, many of the studies considered by this meta-analysis included subjects at low risk for osteoporotic fracture. For instance, in the ViDA trial (20) , only 2% of the vitamin D-supplemented group and 1% of the placebo group were affected by osteoporosis at baseline. It is also worth mentioning that roughly 46% of the enrolled subjects (in both groups) reported a history of fracture. However, given the low prevalence of osteoporosis and in the absence of further details, this data looks more confusing than informative, since most of those fracture events are arguably of traumatic nature and unrelated to bone health status. Further important considerations concern the age of the population involved in these studies: 41% of the patients were under 65 years of age and therefore quite unlikely to be at risk for falling. It is conceivable that all these critical points taken together might have contributed to the moderate heterogeneity observed.
Of the 81 studies considered, 42 evaluated fractures, 37 falls and 41 BMD. However, the authors themselves recognized that only 10 (23.8%) studies were considered valid (low risk of bias) for fracture (5). In our opinion, the most relevant limitation of this meta-analysis, and of the previous ones as well, lies in the fact that most of the studies enrolled individuals who were not vitamin D deficient (>20 ng/mL) or who even attained sufficient levels (30 ng/mL) and were therefore unlikely to experience any benefit (21) . Vitamin D deficient patients (i.e. 25OHD <25 nmol/L or <10 ng/ mL) only accounted for 831/39,485 (2.1%) of the total patients in Bolland's metaanalysis (5)! This is a recurrent limitation affecting the studies published in the literature, and it originates from the assumption of vitamin D acting as a pharmacological agent, while it should be considered a micronutrient instead (21) . Therefore, it is not surprising if its supplementation shows efficacy only in deficient subjects (21) . Flaws in the study population selection may also be found in the Vitamin D Assessment (ViDA) Study (20) , a recent large trial included in Bolland's meta-analysis. The ViDA trial is a randomized, doubleblind, placebo-controlled trial that involved 5110 healthy volunteers aged 50-84 years, randomly assigned to receive either an initial oral dose of 200,000 IU cholecalciferol followed by monthly 100,000 IU cholecalciferol or equivalent placebo dosing, with a mean treatment duration of 3.4 years. The mean blood 25OHD concentration at baseline was 63 nmol/L (25.2 ng/ mL). Only about 2% of the subjects were 25OHD deficient, while over 30% had values even higher than ideal thresholds (i.e. 25OHD>75 nmol/L or 30 ng/mL). As expected, the results failed to prove any benefit: the monthly high-dose boluses of cholecalciferol were not able to prevent falls or fractures in this healthy, ambulatory, adult population, without vitamin D deficiency. Nevertheless, it is interesting to note that a recent sub-analysis of the ViDA study, focusing on central blood pressure parameters, showed consistently favourable changes among the participants with vitamin D deficiency at baseline (<50 nmol/L), while nonsignificant changes in all hemodynamic parameters were found in the overall sample (22) . Interestingly, a few days after his metaanalysis, Bolland published two papers in which he stated that most of the available studies evaluating vitamin D supplementation can be considered research waste (1, 2), given the inclusion of a large proportion of vitamin D sufficient participants that is likely to have diluted the data on the benefits of vitamin D supplementation in the deficient ones. We completely agree with Bolland's statements and we are also concerned that meta-analyses stemming from these studies may be tainted to a similar extent. In this regard, some authors suggest that future trials on vitamin D supplementation should recruit participants with low vitamin D levels (all with 25OHD<50 nmol/L, and a good proportion with <25 nmol/L) and also suggest avoidance of supplementation with low-dose vitamin D in the placebo group. Unfortunately, we doubt that this proposal will represent a viable strategy in the future, especially given its clear ethical implications. Contributions: all the authors contributed equally.
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